User login
Dr. Vincent A. Miller describes study results that suggest the addition of erlotinib to bevacizumab treatment for advanced non-small cell lung cancer extends progression-free survival compared with bevacizumab alone. Damian McNamara of the Global Medical News Network (GMNN) reports from the annual meeting of the American Society of Clinical Oncology in Orlando.
Dr. Vincent A. Miller describes study results that suggest the addition of erlotinib to bevacizumab treatment for advanced non-small cell lung cancer extends progression-free survival compared with bevacizumab alone. Damian McNamara of the Global Medical News Network (GMNN) reports from the annual meeting of the American Society of Clinical Oncology in Orlando.
Dr. Vincent A. Miller describes study results that suggest the addition of erlotinib to bevacizumab treatment for advanced non-small cell lung cancer extends progression-free survival compared with bevacizumab alone. Damian McNamara of the Global Medical News Network (GMNN) reports from the annual meeting of the American Society of Clinical Oncology in Orlando.